Cell Therapeutics May Be Banking Too Much on Lymphoma Drug

The Burrill Report submits:

Zacks.com submits: Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone.

Zacks.com submits: Cell Therapeutics Inc. (CTIC) received a boost when the European Medicines Agency (EMEA) validated the expanded Pediatric Investigation Plan (PIP) filed by the company in July this year for its lead candidate pixantrone.

Zacks.com submits: In an attempt to guard itself against hostile takeover, Cell Therapeutics (CTIC) adopted a shareholder rights plan. The plan, to be effective from Jan 7, 2010, has been designed so that a potential buyer has to discuss any offer with Cell Therapeutics' board of directors before approaching the shareholders directly.

Jeremy Richards submits:Cell Therapeutics (CTIC) is worth buying, in my opinion. There are only seven trading days until CTIC investors may get some very exciting news.

By M.E. Garza: Very early on Monday morning, Cell Therapeutics, Inc. (NASDAQ:CTIC) told Wall Street that they need additional time to prepare for the highly anticipated review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee ("ODAC") at its February 9, 2012 meeting.

The Burrill Report submits: Reviewers with the U.S. Food and Drug Administration questioned both the safety and efficacy of Forest Laboratories’ (FRX) and Nycomed’s once-daily pill Daxas for the treatment of chronic obstructive pulmonary disease, Reuters reported.

By Brian Nichols:The Lancet is one of the more credible resources in the field of medicine and biotechnology with its three journals: infectious disease, neurology, and oncology. Writings from it tend to be well informed, well researched, well prepared, and highly objective for its readership.